학술논문
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Document Type
Article
Author
van der Heijde, Désirée; Cheng-Chung Wei, James; Dougados, Maxime; Mease, Philip; Deodhar, Atul; Maksymowych, Walter P; Van den Bosch, Filip; Sieper, Joachim; Tomita, Tetsuya; Landewé, Robert; Zhao, Fangyi; Krishnan, Eswar; Adams, David H.; Pangallo, Beth; Carlier, Hilde; Churchill, Melvin; Flint, Kathleen; Gladstein, Geoffrey; Greenwald, Maria; Howell, Mary; Ince, Akgun; Kaine, Jeffrey; Mehta, Daksha; Peters, Eric; Querubin, Roel; Reveille, John; Roseff, Richard; Diegel, Roger; Thai, Christine; Bessette, Louis; Morin, Frederic; Rahman, Proton; Barrera Rodriguez, Aaron Alejandro; Cons-Molina, Fidencio; Duran Barragan, Sergio; Skinner, Cassandra; Pacheco Tena, Cesar; Ramos Remus, Cesar; Rizo Rodriguez, Juan Cruz; Hong, Seung-Jae; Lee, Yeon-Ah; Ju, Ji Hyeon; Kang, Seong Wook; Kim, Tae-Hwan; Lee, Chang Keun; Lee, Eun Bong; Lee, Sang Heon; Park, Min-Chan; Shin, Kichul; Lee, Sang-Hoon; Chen, Hung-An; Chen, Ying-Chou; Hsieh, Song-Chou; Lan, Joung-Liang; Dvorak, Zdenek; Moravcova, Radka; Malcova, Martina; Taniguchi, Yoshinori; Kishimoto, Mitsumasa; Tada, Kurisu; Dobashi, Hiroaki; Inui, Kentaro; Ueki, Yukitaka; Matsumoto, Yoshifuji; Koyama, Yoshinobu; Hatta, Kazuhiro; Atsumi, Tatsuya; Goto, Hitoshi; Matsui, Kiyoshi; Takakubo, Yuya; Neeck, Gunther; Poddubnyy, Denis; Rubbert-Roth, Andrea; Szymanska, Malgorzata; Blicharski, Tomasz; Dudek, Anna; Racewicz, Artur; Wojciechowski, Rafal; van de Sande, Marleen; Griep, Ed; Nurmohamed, Mike; Matsievskaya, Galina; Shmidt, Evgeniya; Stanislav, Marina; Yakushin, Sergey; Ershova, Olga; Rebrov, Andrey; Balazs, Tibor; Cseuz, Regina; Drescher, Edit; Poor, Gyula
Source
The Lancet; December 2018, Vol. 392 Issue: 10163 p2441-2451, 11p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when conventional therapies are not effective. We report efficacy and safety data on ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), in patients with radiographic axial spondyloarthritis who have not previously been treated with bDMARDs.